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Psoriasis is a common immune-mediated disorder that affects
the skin, nails and joints. To identify psoriasis susceptibility
loci, we genotyped 438,670 SNPs in 1,409 psoriasis cases
and 1,436 controls of European ancestry. We followed up 21
promising SNPs in 5,048 psoriasis cases and 5,041 controls.
Our results provide strong support for the association of at
least seven genetic loci and psoriasis (each with combined
P o 5  108). Loci with confirmed association include
HLA-C, three genes involved in IL-23 signaling (IL23A, IL23R,
IL12B), two genes that act downstream of TNF-a and regulate
NF-jB signaling (TNIP1, TNFAIP3) and two genes involved in
the modulation of Th2 immune responses (IL4, IL13). Although
the proteins encoded in these loci are known to interact
biologically, we found no evidence for epistasis between
associated SNPs. Our results expand the catalog of genetic loci
implicated in psoriasis susceptibility and suggest priority targets
for study in other auto-immune disorders.
Psoriasis is a common inflammatory disease affecting B1% of indi-
viduals. The most obvious cellular features of psoriasis are epidermal
hyperplasia, altered keratinocyte differentiation and inflammation1.
Psoriasis susceptibility has a genetic component, partly explained by
association between psoriasis and major histocompatibility complex
(MHC) haplotypes bearing HLA-Cw6 (ref. 2) and SNPs near IL12B
and IL23R3. Individuals with psoriasis show increased risk for
other immune-mediated disorders4 and some IL12B and IL23R
polymorphisms are associated with Crohn’s disease and ulcerative
colitis in addition to psoriasis (for an example, see ref. 5).
To identify additional psoriasis susceptibility loci, we carried out a
genome-wide association scan of 1,409 psoriasis cases and 1,436
controls in partnership with the Genetic Association Information
Network (GAIN)6 (see Table 1 and Supplementary Table 1 online
for details of case and control collections). After samples were
genotyped at Perlegen Sciences, we used a dataset that passed quality
control filters and included 438,670 autosomal SNPs genotyped in
1,359 psoriasis cases and 1,400 controls to impute genotypes for
2.5 million HapMap SNPs (see Methods).
An initial comparison of case-control allele frequencies (genomic
control l ¼ 1.033) confirmed association at established susceptibility
loci HLA-C (rs12191877, P ¼ 4  1053), IL12B (rs2082412, P ¼ 5 
1010) and IL23R (rs2201841, P ¼ 3  107). Encouraged by these
results, we selected 21 SNPs (representing 18 independent loci, see
Methods) for genotyping in an additional 5,048 cases and 5,051
controls (see Table 1 and Supplementary Table 2 online). We
found supporting evidence of association at 10 of these 18 loci
(P o 0.05 in the follow-up sample, direction of effect matches
discovery sample; Table 2). Evidence for association was particularly
compelling at seven of these loci (P o 0.0005 in follow-up samples,
combined P value o5  108). Owing to the ‘winner’s curse’, odds
ratios estimated in the discovery sample were larger than those
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estimated in the follow-up samples. To minimize this effect, we use
follow-up sample odds ratios in the discussion that follows. Figure 1
summarizes the results of the association scan, with the seven
regions of confirmed association detailed in Figure 2. Overall, our
approach providesB70% power to detect loci that are well tagged by
genotyped SNPs, increase disease risk by 41.35-fold and have a
frequency 420%.
The results highlight the role of several key pathways in disease
susceptibility. First, three SNPs with strong evidence of association
map near IL12B (encoding the p40 subunit of IL-23 and IL-12), IL23A
(encoding the p19 subunit of IL-23) and IL23R (encoding a subunit
of the IL-23 receptor): rs2082412 (risk allele frequency in controls
fcontrol ¼ 0.80, odds ratio in follow-up samples ORfollow-up ¼ 1.44,
combined P value Pcombined ¼ 2  1028), rs2066808 (fcontrol ¼ 0.93,
ORfollow-up ¼ 1.34, Pcombined ¼ 1  109) and rs2201841 (fcontrol ¼
0.29, ORfollow-up¼ 1.13, Pcombined¼ 3 108). Genetic variants in the
IL23A locus are implicated in psoriasis and autoimmune disease
susceptibility for the first time by our study. IL-23 signaling promotes
cellular immune responses by promoting the survival and expansion
of a recently identified subset of T cells expressing IL-17 that protects
epithelia against microbial pathogens7. Dysregulated IL-23 signaling
could predispose certain individuals to inappropriate chronic immune
responses that target epithelial cells and ultimately result in psoriasis.
Second, loci including TNFAIP3 (TNF-a induced protein 3) and
TNIP1 (TNFAIP3 interacting protein 1), whose gene products work
downstream of TNF-a to regulate NF-kB, show strong association
Table 1 Summary description of the samples used in this study
Cases Controls
N Mean age at onset Male (%) Psoriatic arthritis (%) N Mean age at exam Male (%) Total
Discovery samples
Collection of J.T. Elder 480 23.0 52.1 25.2 702 40.5 49.3 1,182
Collection of G. Krueger 476 28.4 42.9 30.0 473 29.7 42.7 949
Collection of A. Bowcock 453 27.2 49.9 26.5 261 57.4 36.0 714
Discovery sample total 1,409 26.1 48.3 27.1 1,436 40.0 44.7 2,845
Follow-up samples
Collection of J.T. Elder 1,642 30.8 46.3 16.4 1,101 48.0 41.0 2,743
Collection of M. Weichenthal 718 25.1 52.1 16.7 1,464 40.4 51.0 2,182
Celera follow-up set 1, A. Begovich 498 29.4 44.6 40.7a 498 47.4 44.6 996
Celera follow-up set 2, A. Begovich 483 26.8b 53.4 29.3a 427 44.3b 52.2 910
Collection of D. Gladman 691 29.4 59.9 71.6 217 41.8 47.7 908
Collection of J. Fischer 346 19.0 45.2 13.9 486 n/ac 47.2 832
Collection of A. Bowcock 302 28.0 49.0 34.1 500 59.0 48.0 802
Collection of P. Rahman 368 28.3 47.8 81.5 358 54.9 43.0 726
Follow-up sample total 5,048 5,051 10,099
All cases and controls were of white European ancestry.
aIn the Celera case samples, subjects were only classified as psoriatic arthritis positive or negative ten years after disease onset. In follow-up set 1, 98 of 241 subjects followed-up
for 410 years had psoriatic arthritis. In follow-up set 2, 63 of 215 subjects met this criterion. bInformation on age at disease onset and age at exam was available for 293 cases and 292
controls, respectively. cAge information for controls in this sample set was not tracked electronically in the sample database and is not readily accessible.
Table 2 Loci with strongest evidence of association with psoriasis in the combined sample, including discovery and follow-up samples
Discovery samples
(1,359 cases, 1,400 controls)
Follow-up samples
(5,048 cases, 5,051 controls)
Frequencya Frequency
SNP Chr.
Pos.
(Mb)
Alleles
risk/nonrisk Case Control OR P valueb Case Control
OR
(meta)
P valueb
(meta)
Combined
P valued
Notable nearby genes
(relative position)c
rs12191877 6 31.36 T/C 0.313 0.141 2.79 4  1053 0.301 0.147 2.64 o10100 o10100 HLA-C (–13 kb)
rs2082412 5 158.65 G/A 0.856 0.792 1.56 5  1010 0.848 0.798 1.44 3  1020 2  1028 IL12B (+24 kb)
rs17728338 5 150.46 A/G 0.093 0.056 1.72 2  107 0.087 0.054 1.59 6  1015 1  1020 TNIP1 (–12 kb)
rs20541 5 132.02 G/A 0.832 0.783 1.37 6  106 0.827 0.790 1.27 1  1010 5  1015 IL13 (nonsynonymous)
rs610604 6 138.24 G/T 0.374 0.318 1.28 1  105 0.360 0.320 1.19 7  108 9  1012 TNFAIP3 (intronic)
rs2066808d 12 55.02 A/G 0.958 0.931 1.68 2  105 0.947 0.932 1.34 5  106 1  109 IL23A (+3.7 kb)
STAT2 (intronic)
rs2201841 1 67.47 G/A 0.350 0.286 1.35 3  107 0.325 0.295 1.13 4  104 3  108 IL23R (intronic)
rs1076160 9 134.80 T/C 0.520 0.463 1.26 2  105 0.496 0.475 1.09 4  103 6  106 TSC1 (intronic)
rs12983316 19 10.98 G/A 0.186 0.144 1.36 2  105 0.159 0.147 1.09 0.027 8  105 SMARCA4 (intronic)
rs397211 2 113.60 T/C 0.718 0.677 1.21 1  103 0.709 0.696 1.08 0.025 4  104 IL1RN (+0.5 kb)
aFrequency of the risk allele. bAll P values are two tailed. cPosition of each SNP relative to notable nearby genes is given. Plus (+) and minus () signs indicate whether the SNP is upstream (–) or
downstream (+) of the transcription start site. SNPs that overlap the gene are labeled as ‘intronic’, ‘synonymous’ or ‘nonsynonymous’. dGenotypes for rs2066808 were imputed using MaCH. The
distribution of imputed posterior probabilities for each genotype was then compared between cases and controls.
Similar evidence for association was observed at rs2066807 (combined P ¼ 2  109), which maps nearby and was genotyped in discovery and follow-up samples. Boldface rows indicate loci
achieving a genome-wide level of significance (P o 5  10–8) in the combined analysis.
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with psoriasis. In these two regions, markers rs610604 (fcontrol ¼ 0.32,
ORfollow-up ¼ 1.19, Pcombined ¼ 9  1012) and rs17728338 (fcontrol ¼
0.05, ORfollow-up ¼ 1.59, Pcombined ¼ 1  1020) were sites of
replicated association. TNFAIP3 encodes A20, a TNF-a-inducible
zinc-finger protein that temporally limits immune responses by
inhibiting NF-kB activation and terminating NF-kB mediated
responses8. Symptoms in a mouse model of psoriasis induced by
administration of IL-23 are ameliorated by blocking of TNF-a9 and, in
a different mouse model, a region of mouse chromosome 10 encom-
passing Tnfaip3 promotes psoriasis in a TNF-a–dependent manner10.
Notably, this same region of the mouse genome has been also
associated with atherosclerosis11, a major co-morbidity of psoriasis12.
Monoclonal antibodies targeting TNF-a and those targeting the p40
subunit of IL-12 and IL-23 both provide highly efficacious therapeutic
regimens for many individuals with psoriasis13,14; hence, five of the
genes implicated here have key roles in pathways targeted by ther-
apeutic interventions. Further, common polymorphisms near
TNFAIP3 have recently been associated with rheumatoid arthritis
(for example, rs6920220, rs10499194; see ref. 15 for an example)
and systemic lupus erythematosus (for example, rs5029939,
rs13192841, rs2230926 and rs6922466)16,17. However, these poly-
morphisms show no association with psoriasis in our sample (all
P 4 0.30) and are not in linkage disequilibrium (LD, all r2 o 0.03)
with the psoriasis-associated alleles (for example, rs610604).
Third, genes in the two other loci implicated here are also key
modulators of immune response. One locus encodes the IL-4 and IL-
13 cytokines that modulate humoral immune responses mediated by
Th2 cells. In this locus, we replicated association at rs20541 (fcontrol ¼
0.79, ORfollow-up ¼ 1.27, Pcombined ¼ 5  1015). Dysregulation of
IL-4 and IL-13 might polarize the immune response toward Th1-
mediated cellular immune responses such as production of interferon-
g, which supports the marked expansion of IL-17–producing T cells
observed in psoriatic lesions18. Our findings extend the promising
results of a recent study19 to a genome-wide level of significance.
Notably, our IL4 and IL13 signal maps within B200 kb of the IBD5
Crohn’s disease susceptibility locus5. The two are not in LD (for
example, r2 between rs20541 and rs10077785 (ref. 5) in HapMap CEU
is o0.01), but IBD5 does show modest evi-
dence for association with psoriasis
(rs10077785, P ¼ 0.03), suggesting that it could be another locus
that contributes to both diseases.
SNP rs12191877, the genotyped marker showing strongest associa-
tion with psoriasis (fcontrol ¼ 0.15, fcase ¼ 0.30, ORfollow-up ¼ 2.64,
Pcombined oo 10100), was in LD with HLA-Cw6 (r2 ¼ 0.63). In a
subset of cases and controls in which HLA-Cw6 genotypes were
available, HLA-Cw6 was more strongly associated with psoriasis
than any genotyped or imputed SNP, but could not fully account
for all observed association signals (data not shown). To assess the
evidence for multiple psoriasis susceptibility alleles within the MHC,
we implemented a forward-selection procedure to select a set of
disease-associated variants in each locus (see Methods). This analysis
resulted in a model with three imputed SNPs (Supplementary Table 3
online). The first two of these (rs12204500 and rs13191343, forward-
selection P values of 8  1057 and 2  1010, respectively) are close
to and in strong LD with HLA-Cw6 (r2 ¼ 0.78 and 0.52, respectively),
whereas the third one (rs2022544, P value ¼ 107) maps closer to the
HLA-DR gene cluster and shows only weak LD with HLA-Cw6 (r2 ¼
0.01). These results endorse a search for additional psoriasis suscept-
ibility loci within the MHC.
When we applied the same forward-selection strategy to the other
loci, two independent SNPs (r2o 0.01) were selected in the IL12B and
IL23R regions. Although only one SNP was selected in the four other
regions (Supplementary Table 3), it is likely that independent disease-
associated alleles exist in additional loci such as TNIP1 where rs884520
(a SNP onlyB6 kb away from the peak of association at rs17728338)
was suggestively associated with psoriasis (P ¼ 9 105 unadjusted,
P ¼ 0.051 after conservative adjustment for 565 independent tests) in
our conditional analyses. Fully characterizing the impact of these loci
on psoriasis susceptibility will require characterization of the full
spectrum of allelic variation at each locus in large case-control samples.
As all the loci implicated here are involved in regulation of immune
responses, and several of the proteins they encode interact physically
(for example, IL-12B/p40 and IL-23/p19 form a heterodimer that
binds to IL-23R, and TNIP1 interacts with TNFAIP3) we assessed
evidence of epistasis in our data. We considered all 21 possible pairings
of the seven lead SNPs, testing for deviation from a log-additive risk
20
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Figure 1 Bird’s eye view of association scan
results. The top panel summarizes the
distribution of test statistics at genotyped SNPs
across the genome. We used a simple w2 test to
compare SNP allele frequencies in cases and
controls and plotted the resulting –log P values
across the genome. Several P values o1020 in
the MHC region were truncated. Loci where we
obtained confirmatory evidence of association in
follow-up samples (see Table 2) are highlighted
in green. The middle panel summarizes the
distribution of test statistics across the genome,
after genotype imputation. We used a simple
t-test to compare imputed allele counts in cases
and controls and plotted the resulting –log P
values across the genome. The bottom panel
displays a quantile-quantile plot for our test
statistics. Results are plotted including all SNPs
(in red), after exclusion of SNPs in the MHC (in
orange) and after exclusion of all SNPs in regions
of replicated association (in blue). The shaded
region represents a 90% confidence interval for
the test statistics.
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model. Only the pairing involving rs12191877 near HLA-C and
rs610604 near TNFAIP3 showed any evidence for epistasis under
this model (P ¼ 0.02 in combined sample). It is possible that
tests of interaction will be more powerful once the causal variants
at each loci have been identified, but it is notable that even when
proteins encoded by the associated loci interact physically no
significant evidence for epistasis was detected (a similar situation
occurs for height20, among other traits).
To evaluate evidence for heterogeneity in the effect sizes at each of
the seven replicated loci, we calculated I2 and Q statistics for a meta-
analysis of follow-up samples (Supplementary Table 4 online). We
observed no evidence for heterogeneity at non-MHC loci, and only
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Figure 2 Evidence for association in confirmed loci. The figure summarizes evidence of association (in the discovery sample) in each region of confirmed
association. Test statistics at the SNP selected for follow-up (typically, the genotyped SNP showing strongest evidence for association in each locus) are
highlighted with a square. Test statistics for other SNPs are drawn as circles and color coded according to the degree of linkage disequilibrium with the
SNP selected for follow-up.
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modest evidence for heterogeneity at rs12191877 in the MHC (P ¼
0.007, Supplementary Table 4)—potentially reflecting sample differ-
ences in the proportion of familial cases and psoriatic arthritis. At
several of the confirmed loci, we found modest differences in associa-
tion signal strength for psoriatic arthritis compared to purely cuta-
neous psoriasis (Supplementary Table 5 online), supporting
epidemiologic evidence for differences in genetic architecture of the
two conditions21. In other stratified analyses, we found no evidence
for heterogeneity between males and females (all P 4 0.15) or
between younger and older individuals (all P 4 0.15, cases and
controls stratified around median ages).
Psoriatic and uninvolved skin show significantly different expres-
sion for hundreds of genes, involved in both immune response and in
the regulation of cellular differentiation and proliferation22. We
reasoned that altered expression of genes in the loci implicated by
our study might also be a molecular trigger in disease progression.
Therefore, we examined expression of the genes in the loci showing
replicated evidence of association in skin biopsies from 64 GWAS
controls and in biopsies of involved and uninvolved skin from 58
GWAS cases (Supplementary Table 6 and Supplementary Fig. 1
online). Together, these results show that four of the genes investigated
(HLA-C, IL12B, TNIP1 and IL23A) show highly significant differences
in expression between involved and uninvolved skin (all with P o
109). Two of these (IL23A, TNIP1) also showed differences in
expression when we compared normal skin from controls and unin-
volved skin from cases (P o 0.0003). The results are consistent with
the hypothesis that the expression of particular HLA-C alleles and of
IL23A and IL12B (encoding the two subunits of IL-23) in psoriatic
skin are key events in disease progression. However, the dosage of risk
alleles at the seven psoriasis-associated SNPs did not correlate with
transcript levels for nearby genes in either involved, uninvolved or
normal skin. It remains possible that association between these SNPs
and gene expression patterns is stronger at specific time points during
development, disease progression or in specific cell types.
Although this study represents a significant advance in our under-
standing of the genetic underpinnings of psoriasis, much work
remains to be done. The association signals identified here account
for a sibling recurrence risk (ls) of o1.35 (including B1.25 due to
HLA); consequently, much of the overall sibling recurrence risk for
psoriasis, which has been estimated at approximately three- to
sixfold23, remains unexplained. Still, the rapid pace of advance in
psoriasis genetics is encouraging. In the past 18 months, the number
of independent genetic loci confidently associated with psoriasis has
increased from one (HLA-Cw6 and other MHC variants) to at least
ten, including the seven association signals reported in this paper, copy
number variants in the beta-defensin24 and late cornified envelope
(LCE) gene regions25, and a signal near RNF114, a potential regulator
of T-cell activation26. The RNF114 signal is supported by our data (see
Supplementary Table 7 online for analysis of previously reported
GWAS26,27 signals in our data). Although we did not systematically
characterize copy number variation, we note that rs4112788, a SNP
proxy for the LCE deletion25,27, is associated with disease in our
discovery sample (P ¼ 0.001). In each of the loci identified here, fine-
mapping and resequencing efforts together with further functional
studies are required to pinpoint and characterize causal variants,
confirm the identity of the implicated genes, and accurately quantify
the contribution of the locus to disease susceptibility. In parallel,
follow-up analyses with larger numbers of SNPs, execution of
genome-wide association scans in larger sample sets, meta-analyses
of genome-wide scan results, and large scale analyses of rarer variants
should lead to identification of additional susceptibility loci.
METHODS
Informed consent. All participating subjects gave informed consent and
protocols were reviewed and approved by local institutional review boards.
Genotyping. Perlegen Sciences genotyped discovery samples using four pro-
prietary, high-density oligonucleotide arrays. SNPs on the arrays were selected
to tag common variation in samples of European ancestry. Cases and controls
from the same collection were genotyped together, and arranged to ensure
similar proportions of cases and controls in each plate. Follow-up samples were
genotyped using either Applied Biosystems Taqman assays, Sequenom single
base extension assays, or allele-specific kinetic PCR. The 21 SNPs selected for
follow-up included 19 SNPs selected to represent loci with strongest evidence
for association in our initial scan (including 2 SNPs per locus for hits near IL13,
IL23A and PRKRIP1) and two SNPs in loci that included strong functional
candidates (IL1RN and CNTN5) but more modest evidence of association
(rs397211, P ¼ 1  103, and rs12807920, P ¼ 1  104).
Sample quality control. Eighteen samples failed genotyping for technical
reasons. Among the remaining samples, we excluded those with call rates
o95% (8 samples) and with outlier heterozygosities of o31% or 434%
(24 samples; the average heterozygosity for all samples was 32.6% with s.d. of
0.4%). We also excluded one individual from each pair of unexpected
duplicates, first- or second-degree relatives (36 individuals). This resulted in
a dataset with 1,359 cases and 1,400 controls.
Quality control of genotype data. Perlegen Sciences called450% of genotypes
for 556,383 SNPs. Before analysis, we excluded markers with o95% genotype
call rates (99,963 SNPs), with minor allele frequency o1% in the combined
dataset (6,106 SNPs), with HWE P value o106 (2,962 SNPs), with 42
mismatches among 48 duplicate pairs (62 SNPs) or with 42 mendelian
inconsistencies among 27 trios (41 SNPs). In total, 447,249 SNPs passed the
quality control filters (average call rate of 99.2%). Here, we present analyses of
438,670 autosomal SNPs.
Genotype imputation. As previously described28, we used information on
patterns of haplotype variation in the HapMap CEU samples (release 21)29 to
infer missing genotypes ‘in silico’. We only analyzed SNPs that were genotyped
or could be imputed with relatively high confidence (estimated r2 between
imputed SNP and true genotypes 40.3, so that patterns of haplotype sharing
between sampled individuals and HapMap samples consistently indicated a
specific allele).
Assessment of genotyping and imputation quality. A single plate containing
90 study samples was re-genotyped for 906,600 SNPs using the Affymetrix 6.0
chip. Comparison of 15,844,334 genotypes for 218,039 SNPs overlapping
between the Perlegen and Affymetrix platforms resulted in an observed discre-
pancy rate of 0.25% per genotype (0.12% per allele). Comparison of 57,747,244
imputed and experimentally derived genotypes for 661,881 non-Perlegen SNPs
present in both our imputed SNP set and the Affymetrix 6.0 array resulted in a
discrepancy rate of 1.80% per genotype (0.91% per allele). Overall, the average r2
between imputed genotypes and their experimental counterparts, which pro-
vides an estimate of the relative power of analysis relying on imputation instead
of direct genotyping, was 0.93. This r2 statistic exceeded 0.80 for490% of SNPs,
suggesting excellent coverage of common variation in the genome.
Association analyses. To evaluate the evidence for association between each
genotyped or imputed SNP and psoriasis, we first calculated a single w2 statistic
that contrasted observed or imputed allele counts between cases and controls.
The 832 follow-up samples collected by J. Fischer (Table 1) and colleagues were
analyzed using a family-based approach30. To combine statistics across different
samples, we first selected an arbitrary reference allele for each marker and then
calculated a z statistic characterizing the evidence for association in each study
(summarizing both the P value, in its magnitude, and the direction of effect, in
its sign). We then calculated an overall z statistic as a weighted average of the
individual statistics and calculated the corresponding P value. Weights were
proportional to the square root of the number of individuals examined in each
sample and were selected such that the squared weights sum to 1.0.
Forward selection procedure. We first selected the SNP that showed strongest
association in each region. Then, conditioning on this SNP, we searched for the
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next most strongly associated SNP. If evidence for association at this second
SNP was stronger than expected by chance (after adjusting for the number of
SNPs tested), we sought a third strongly associated SNP and so forth.
Gene expression. We obtained 6 mm punch skin biopsies at the University of
Michigan Department of Dermatology. One biopsy of normal skin was obtained
from the buttock of 64 control individuals. Two biopsies (one involved, one
uninvolved) were obtained from 58 psoriatic subjects. Involved skin biopsies
were taken from psoriasis plaques, and uninvolved skin biopsies were taken from
the buttocks, at least 10 cM away from the nearest plaque. RNA from each
biopsy was isolated using the RNeasy kit (Qiagen). Samples were run on
Affymetrix U133 Plus 2.0 arrays to evaluate expression of B54,000 probes
according to the manufacturer’s protocol. The raw data from 180 microarrays
was processed using the Robust Multichip Average (RMA) method. Prior to
analysis, we adjusted RMA expression values to account for batch and sex effects.
To obtain a single expression value for each gene, we calculated the average of
expression values of multiple probe sets on the microarray that were mapped to
the same gene. Gene expression was contrasted between different groups of
samples using two sample t-tests (for comparisons involving skin from normal
controls and individuals with psoriasis) or paired t-tests (for comparisons
involving involved and uninvolved skin from affected individuals). Comparisons
of normal skin from controls and psoriatic skin from cases gave similar results
(but slightly more significant P values) to paired comparisons of involved and
uninvolved skin from the same affected individual and are not shown. Reanalysis
of a previously published dataset22 including paired biopsies of involved and
uninvolved skin from 16 individuals gave results consistent with those reported
here, suggesting that IL23A, IL12B and TNIP1 are overexpressed in involved
skin. This independent dataset did not suggest differential expression of HLA-C.
Accession codes. dbGAP: genotype and phenotype data described in this
manuscript have been deposited with accession code phs000019.v1.p1. NCBI
GEO: microarray data have been deposited under accession number GSE13355.
Note: Supplementary information is available on the Nature Genetics website.
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